Prab: CSV import

2025-03-18T01:10:50Z

CSV import

← Older revision		Revision as of 01:10, 18 March 2025
Line 24:		Line 24:
	__NOINDEX__		__NOINDEX__
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-11T07:02:36Z

CSV import

← Older revision		Revision as of 07:02, 11 February 2025
Line 23:		Line 23:
	{{pharma-stub}}		{{pharma-stub}}
	__NOINDEX__		__NOINDEX__
			{{No image}}

Prab: CSV import

2025-02-08T21:28:35Z

CSV import

← Older revision		Revision as of 21:28, 8 February 2025
Line 22:		Line 22:
	[[Category:Signal transduction]]		[[Category:Signal transduction]]
	{{pharma-stub}}		{{pharma-stub}}
			__NOINDEX__

Prab: CSV import

2024-03-30T03:59:33Z

CSV import

New page

'''Vascular Endothelial Growth Factor A''' ('''VEGF-A''') is a protein that plays a critical role in the process of [[angiogenesis]], which is the formation of new [[blood vessels]] from pre-existing vessels. This process is vital for the growth and development of tissues and organs, as well as in the healing of wounds. VEGF-A is part of the VEGF family, which includes several proteins, but VEGF-A is the most studied and significant member due to its specific actions in angiogenesis.

==Function==
VEGF-A acts primarily on [[endothelial cells]], which line the interior surface of blood vessels. It binds to specific [[receptors]] on the surface of these cells, primarily VEGF receptor-1 (VEGFR-1) and VEGF receptor-2 (VEGFR-2). This binding initiates a series of signaling pathways that lead to endothelial cell proliferation, migration, and new blood vessel formation. VEGF-A also increases vascular permeability, allowing for the transport of nutrients and cells that can aid in tissue growth and repair.

==Gene and Structure==
The gene for VEGF-A is located on the human chromosome 6p21.1. The protein itself is a dimer, consisting of two identical or nearly identical subunits. There are several isoforms of VEGF-A, which arise due to alternative splicing of the mRNA transcript. These isoforms vary in their ability to bind to receptors and in their potency in inducing angiogenesis.

==Clinical Significance==
VEGF-A has been implicated in a variety of diseases, primarily those involving abnormal angiogenesis. In [[cancer]], tumors can secrete VEGF-A to promote the formation of new blood vessels, a process known as tumor angiogenesis, which supplies the growing tumor with oxygen and nutrients. This has made VEGF-A a target for [[cancer therapy]], with several drugs developed to inhibit its action.

In [[ophthalmology]], abnormal angiogenesis in the eye, stimulated by VEGF-A, can lead to diseases such as [[diabetic retinopathy]] and [[age-related macular degeneration]] (AMD). Anti-VEGF therapies have been effective in treating these conditions by inhibiting the abnormal growth of blood vessels in the retina.

==Therapeutic Applications==
Several therapeutic agents targeting VEGF-A or its receptors have been developed and are used in the treatment of various diseases. These include monoclonal antibodies, soluble receptors, and small molecule inhibitors. The use of anti-VEGF therapies has become a standard treatment for certain types of cancer and eye diseases, demonstrating the critical role of VEGF-A in disease pathology and its potential as a therapeutic target.

==Conclusion==
VEGF-A is a pivotal factor in the regulation of angiogenesis, with significant implications for both physiological and pathological processes. Its role in disease has made it a key target for therapeutic intervention, leading to the development of treatments that have had a profound impact on diseases characterized by abnormal angiogenesis.

[[Category:Growth factors]]
[[Category:Angiogenesis]]
[[Category:Signal transduction]]
{{pharma-stub}}

VEGF-A - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import

Prab: CSV import